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Abstract
This chapter discusses effective diagnostics and treatment of canine hepatic 
carcinoma (CHC), where state-of-the-art global technologies are complemented by 
traditional Chinese veterinary medicine (TCVM). The biokinetic Ga-67 model of 
CHC is proposed to clarify the Ga-67 metabolic mechanism among various organs. 
It is aimed at identifying the best routine for detecting the metastatic or primary 
CHC and substantiating the optimal further treatment. The routine examina-
tion of CHC can be performed via Ga-67 nuclear examination or MRI, biological 
index, X-ray, and abdominal ultrasound. The available methods of animal cancer 
treatment imply separate or combined application of surgery, radiation therapy, 
and chemotherapy targeted at the particular cancer cells. However, there is also a 
general concern on the quality of life of pets/canine patients. This leaves enough 
space to the TCVM (including acupuncture and famous herbal drugs) with a long 
application history in Asia and growing usage as alternative treatment in other 
regions. However, its current applications to domestic animals/pets suffering from 
carcinomas are based on individual expert opinions, while there are no outlined 
veterinary treatment strategies and guidelines for clinical practice in this field. A 
comprehensive combination of state-of-the-art global technologies and TCVM is 
considered instrumental in curing canine hepatic carcinoma.
Keywords: canine hepatic carcinoma, nuclear examination, Ga-67 biokinetic model, 
traditional Chinese veterinary medicine, acupuncture
1. Introduction
1.1 Motivation and purpose
Dog owners are aware of the sad fact that their pets are vulnerable to various 
tumors that may occur at any age/location and cause severe complications. In par-
ticular, canine hepatic tumors correspond to 0.6 to 1.3% of canine neoplasms, while 
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about 7–36% of dogs are metastasized from other organs [1–9]. The canine patients, 
which usually suffer from systemic metabolic stress and cachexia, require a surgery 
or chemotherapy based on the veterinarians’ recommendations and life expecta-
tions. Noteworthy is that different tumor types of primary carcinoma can arise from 
different cell types listed in Table 1 [2]. The major types of primary liver cancer are 
hepatocellular carcinoma (HCC), bile duct carcinoma, neuroendocrine (carcinoid) 
tumor, and mesenchymal tumor (sarcoma). Hepatocellular carcinoma (HCC) is 
generally found in dogs, especially elder ones. Compared with the modular or diffuse 
forms, the majority of HCC has a lower rate of metastasis. A single massive HCC 
tumor can usually be removed by surgical treatment. However, the most difficult 
clinical treatment is the diffuse HCC involving in the entire liver. Dogs with multiple 
liver lobes’ HCC are not recommended to undergo surgical resection, have a poor 
prognosis and very limited treatment options [2–4, 10–13]. Bile duct carcinomas are 
the second common malignant liver tumor in dogs. Neuroendocrine tumors are quite 
rare and mostly nodular or diffuse, while primary liver sarcomas, including hem-
angiosarcoma, fibrosarcoma, and hepatocellular carcinoma, are unusual clinically. 
Dogs with liver tumors can be either asymptomatic or exhibit nausea, vomiting, 
weight loss, loss of appetite, diarrhea, lethargy, or PU/PD. Occasionally, yellowing 
of the skin and eyes like jaundice, or neurological signs (hepatic encephalopathy), 
such as seizures, disorientation, and weakness, are observed. Liver carcinoma grows 
slowly and manifests itself too late [2–6, 14–16]. This study attempts to set up the 
Ga-67 nuclear examination protocol for liver carcinoma canine patients, which 
would guide the veterinary expert and dog owner on the further optimal treatment: 
intensive surgery/chemotherapy or/and traditional Chinese veterinary medicine.
1.2 Definition of critical terminology
In this study, the global state-of-the-art approach to the above problem implies the 
conventional medicine based on modern science and advanced evaluation methods 
of canine physical and biochemical conditions. The respective treatment methods 
include chemotherapy, drugs, radiology, and surgery. Local tumor ablation and 
radiotherapy have been applied in veterinary medicine for decades. Chemotherapy is 
related to the use of several anti-cancer drugs administered intravenously, orally, or 
subcutaneously, which circulate in the patient’s body and attack cancer cells. The most 
common chemotherapy drugs for treating liver cancer are listed in Table 2. Alkylating 
agents react with DNA strands and change the DNA structure. The commonly utilized 
Classification Types
1. Hepatocellular a. Hepatic adenoma
b. Hepatocellular carcinoma  
c. Hepatoblastoma
2. Biliary a. Biliary adenoma (or cystadenoma)  
b. Biliary carcinoma
3. Neuroendocrine a. Neuroendocrine carcinoma or carcinoid




e. Malignant mesenchymoma f. Chondrosarcoma
Source: DOI: 10.1016/j.cvsm.2016.11.016.
Table 1. 
Primary hepatobiliary tumor types.
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BM* (mild) Variable PO
CCNU (Lomustine) Lymphoma, MCT※ BM*, liver Dogs: 60–90 mg/m2 PO 
q3wk
Cats: 50 to 60 mg/m2 PO or 
10 mg/cat PO q3 to 4wk
Melphalan MMΨ, Plasma cell tumors BM* 0.1 mg/kg/day PO x 10 days, 
then 0.05 mg/kg QOD;
0.2 pulse dose at 7 mg/m2 















Dogs:≧15 kg: 30 mg/m2 IV 
q2 to 3wk
Dogs: < 15 kg: 1 mg/kg IV 
q2 to 3wk








Dogs: 5 to 6 mg/m2 IV q3wk
Cats: 6 to 6.5 mg/m2 IV 
q3wk
Platinum Drugs
Carboplatin Sarcoma, Carcinoma BM*, Gl# Dogs: 300 mg/m2 IV q3wk
Cats: 240 to 260 mg/m2 IV 
q3 to 4wk




Dogs: 70 mg/m2 IV q3wk 
(saline Do not use in cats 
emesis, diuresis)
Antimetabolites
Methotrexate Lymphoma BM* (mild), Gl# 0.8 mg/kg IV once weekly
Cytosine 
arabinoside
Lymphoma BM* (mild), Gl# Variable; SQ , IM. IV.
Gemcitabine Lymphoma, MMΨ,
Carcinoma. feline SCC¶
BM* Limited studies Dogs: 100 
to 1000 mg/m2 IV;  
50 mg/m2
twice/wk. with RTω Cats: 
25 mg/m2 twice/wk.  
with RTω
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alkylating agents in veterinary oncology are chlorambucil, cyclophosphamide, 
melphalan, and lomustine. The common toxicity of cyclophosphamide is related to 
sterile hemorrhagic cystitis. Anthracycline antibiotics exert their cytotoxic effect 
through different mechanisms, including free radical formation, DNA intercalation, 
and protein synthesis inhibition. An example of such medicine is Mitoxantrone, 
which is metabolized in the liver and eliminated via feces and urine. Platinum drugs 
act at the N7 position of guanine and adenine residues, having DNA as their primary 
target and being eliminated via kidneys [6]. Antimetabolites are drugs that interfere 
with enzymes or affect DNA synthesis. Their chemo group, methotrexate, is primar-
ily eliminated via renal excretion. Finally, there are antimicrotubule agents, which 
interfere with the mitotic division process, inhibiting cell division and proliferation.
Quite a recent treatment introduced to veterinary oncology is radiology 
or radiation therapy. It rapidly became one of the most common procedures 
of cancer treatment, insofar as it could be clinically performed when surgical 
resection of the tumor remaining after chemotherapy would be problematic or 
too dangerous. Radiotherapy can make cells unable to replicate and eliminate the 
cell division and proliferation. However, radiation therapy can damage normal 
cells, rather than only malignant ones. A well-designed radiotherapy program 
is intended and designed to maximize tumor effect and minimize normal 
Drug Indications Toxicity Dosage and Route of 
Administration



















0.5 to 0.75 mg/m2 IV 
weekly or every other week
Vinblastine Lymphoma, MCT※ BM*, Gl#,
Perivascular tissue 
reaction
2 to 2.2 mg/m2 IV weekly
Miscellaneous
L-Asparaginase Lymphoma Hypersensitivity 
reaction
400 lU/kg or 10.000 IU/
m2 SQ or IM (10,000 IU 
maximum) weekly
Procarbazine Lymphoma BM*, Gl# Variable; dogs: 50 mg/
m2/day
*: BM; bone marrow, #: Gl; gastrointestinal, §: CLL; chronic lymphocytic leukemia, ※: MCT; mast cell tumor,  
Ψ: MM; multiple myeloma, ω: RT: radiation therapy, ¶: SCC; squamous cell carcinoma.
Source: https://veteriankey.com/chemotherapy/, chapter 44: Chemotherapy.
Alkylating agents react with DNA strands and changing the DNA structure. Anthracycline antibiotics exert their 
cytotoxic effect through different mechanisms, including free radical formation, DNA intercalation, and protein 
synthesis inhibition. Platinum drugs act at the N7 position of guanine and adenine residues, suggesting DNA as 
the primary target of the drug. Antimetabolites are drugs that interfere with enzymes or affect DNA synthesis. 
Antimicrotubule Agents interfere with the mitotic spindle, which inhibits cellular division and proliferation.
Table 2. 
Classification of chemotherapy drugs for treatment.
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tissue effect. The benefit of radiotherapy is a cure for tumors and a split course 
 treatment before surgery or chemotherapy [17].
The alternative approach to the above “targeted instrumental and drug invasion 
into the injured body part” is the overall improvement of the whole body and emo-
tional well-being of a patient. In case of canine patients, this approach is reduced to 
the Traditional Chinese Veterinary Medicine (TCVM), which has been introduced 
several thousand years ago as a system of health care and is being implemented 
globally nowadays as alternative medicine [12]. Briefly, the TCVM has accumulated 
a vast list of robust diagnoses of canine diseases based on basic symptoms and 
appearances (tongue color, skin conditions, iris, pulse, etc.). A veterinarian ana-
lyzes these symptoms and the related overall system problems. The proposed cure is 
TCVM-based herbal medicine aimed to fine-tune the immune system and prevent a 
reoccurrence of an illness or future problem as illustrated in Figure 1 [18, 19].
Figure 1. 
Etiology of neoplasia in TCVM. The factors contributing to form phlegm, qi and blood stagnation, blood 
stasis, and eventually, neoplasia, are summarized. It is shown that qi deficiency is the root of cancer and 
phlegm, qi/blood stagnation, and blood stasis are one part of the branches. (cited from Huisheng Xie, Vanessa 
Preast, TCVM fundamental principles, 2nd edition).
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1.3 Background review and rationale study with reference
Liver carcinoma can be diagnosed or detected by using multiple methods. 
Histological findings are considered the most robust for canine patients. The 
TNM staging system for canine hepatocellular carcinoma (HCC) is summarized 
in Table 3 [20]. Veterinary surgeons may perform additional blood examinations 
to look for signs of liver dysfunction. Surgery is one of the treatments for all liver 
tumors. However, right-sided tumors are more challenging to resect because the 
resection lesion is related to the vena cava [2]. For massive hepatic carcinoma, sur-
gical resection via lobectomy is the treatment when complete resection is accepted 
[10, 11]. The mass ligation for complete lobectomy is not recommended for large 
dogs, or central or right divisional liver tumors, because this method will increase 
the risk of complications, such as bleeding or bile leakage. Surgical stapling devices 
are recommended to perform liver lobectomy; in these devices, overlapping rows 
of staples are quickly placed to attenuate vascular and biliary structures within 
the liver lobe’s hilus. If stages T3, N1, or M1 in Table 3 are confirmed by clinical-
stage evaluations, no surgical resection is recommended [20] because it would 
not remove some malignant liver tumors. Therefore, chemotherapy becomes an 
alternative treatment. Unfortunately, according to many clinical practices and 
references, chemotherapy is not very effective liver carcinoma treatment. Thus, 
HCC treatment with intravenous gemcitabine or carboplatin is no longer per-
formed. Instead, in the last decade, the Metronomic chemotherapy and Sorafenib 
treatment (5 mg/kg, twice daily) became widely used due to lower-dose usage and 
administration ease [6, 7].
Alternatively, radiotherapy is sometimes used to make the liver tumor smaller 
or incapsulate it. However, it is not applicable to most liver tumor cases because of 
its side-effects. The major complication is a radiation heat-induced damage to the 
adjacent unaffected liver tissue. A 3D-CRT (three-dimensional conformal radiation 
therapy) is introduced as a new viable treatment option for canine patients with an 
inoperable massive liver carcinoma. From 6 to 10 Gy per fraction are prescribed on 
the planning target volume, and the total dose is 18–42 Gy with 1 to 2 fractions per 
week [17].
1.4 The innovative features of this study
This study is the first attempt to apply the biokinetic Ga-67 model to canine 
liver carcinoma. The aim is to identify the best routine for detecting the meta-
static or primary hepatic carcinoma and substantiating the optimal further 
treatment.
Classification Stage
Primary tumor (T) T0: no evidence of primary tumor Tl: solitary tumor of any size involving one lobe 
T2: multiple tumors of any size involving multiple lobes
T3: tumor(s) with direct invasion of adjacent organs regional lymph nodes
Regional lymph 
nodes (N)
N0: no regional lymph nodes metastasis
Nl: regional lymph node metastasis
N2: lymph node metastasis Distant metastasis
Distant metastasis 
(M)




The TNM staging system for canine hepatocellular carcinoma.
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1.5 The specific rationale study with a solid description
The biokinetic model of Ga-67 evolution was elaborated in this study for the 
case–control group of canine liver carcinoma via in-vivo gamma camera/8-slice 
CT technique. The circulation of time-dependent concentrations of Ga-67 among 
organs was monitored and simulated. The obtained quantitative data for organs 
and branching ratios among organs were incorporated into the biokinetic model of 
Ga-67 radionuclide administered during the hepatic survey.
2. Diagnosis of canine hepatic carcinoma
Due to the absence of nerves in the liver, the early liver neoplasia is painless. 
Therefore, when canine patients are clinically examined, their liver disease if any is 
diagnosed as moderate or severe.
The clinical symptoms include depression, lack of appetite, vomiting, weight 
loss, diarrhea, PU/PD, abdominal distention, lethargy, icterus, and ascites. The 
neurological disorder is mainly caused by hypoglycemia, hepatic encephalopathy, or 
metastasis of the central nervous system as shown in Figure 2 [9, 21–24].
2.1 Biological index
Hematologic features, including mild non-regenerative anemia, inflamed 
leukocytosis, and thrombocytosis, are common in canine liver tumors [1, 15, 16]. 
Figure 2. 
A 12-year-old female Maltese had distention of the abdomen, was diagnosed with a liver tumor via ultrasound.
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Thrombocytosis is observed in approximately half of canine patients with massive 
HCC [1]. The prolonged blood coagulation (prothrombin time, thrombin time, and 
activated partial thromboplastin time) is rare unless the liver disfunction occurs, 
being observed in only 20% of HCC cases [1, 16].
Serum biochemistry indexes of dogs with hepatic neoplasia are commonly 
increased. Thus, elevated enzyme alanine transaminase (ALT), alkaline phosphatase 
(ALP), and aspartate aminotransferase (AST) are observed in liver tumors. Moreover, 
AST to ALT ratios below one are consistent with HCC or bile duct carcinoma [1].
The increased content of α-Fetoprotein is used as a robust indicator of HCC 
in human patients [23, 24]. This indicator is less suitable for dogs with hepatic 
neoplasia, being intrinsic to other types of canine liver tumors. However, about 
75% of dogs with HCC had increased serum α-Fetoprotein, as reported in [25, 26]. 
Hypoalbuminemia, hypoglycemia, hyperglobulinemia, and elevated bile acid 
concentration are also observed in canine liver tumors.
2.2 X-ray examination
Regular abdominal radiography images of canine patients obtained via a diag-
nostic X-ray device are used for diagnosing, staging liver tumors, and planning the 
surgery operation if any. Abdominal radiography may identify a cranial abdominal 
mass with caudal and lateral recumbency shift of the stomach. Ascites may interfere 
with visualizing a mass as depicted in Figure 3. Assessment of thoracic radiographs 
is considered critical to exclude metastatic disease.
2.3 Abdominal ultrasound examination and MRI
Abdominal ultrasound examinations are applicable to 94% of patients and 
allowed determination of an obvious mass in 99% of these patients. The efficiency 
Figure 3. 
(a) Right lateral recumbency of abdominal radiography. (b) Dorsal ventral recumbency of abdominal 
radiography. Two X-ray images were obtained from a Maltese with icterus and abdominal swelling. The liver 
board line is not obvious, rough, and hepatomegaly.
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of the ultrasound method in detecting hepatic mass has been reported previously 
[1, 16]. In this study, the region containing the pathogenic mass (left, central, or 
right lobes) was correctly identified. This indicates that ultrasound examination is 
very sensitive in the identification of a mass as demonstrated in Figure 4. Besides 
the ultrasound examination, the magnetic resonance imaging (MRI) allows one to 
identify the tumor origin region. A variety of surgical planning modalities benefit 
Figure 4. 
(A) Ultrasonography of right medial liver tumor. (B) Ultrasonography of right lateral liver tumor. Survey 
abdominal sonography 14.5y spayed female cocker spaniel dog before Ga67 examination, several hyperechoic 
nodules are seen within a large hypoechoic portion in the right medial and lateral hepatic lobe.
Canine Genetics, Health and Medicine
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from MRI accuracy in the localization of liver tumors; advanced imaging may be 
needed for precise tumor localization.
2.4 Ga-67 nuclear examination
Canine liver carcinoma cases were analyzed in this study via the nuclear 
examination technology. We have proposed a preliminary/simplified biokinetic 
model according to the general-purpose biokinetic model as recommended by the 
ICRP-30 report, to interpret the empirical data from the clinical examination of a 
case–control group of hepatic carcinoma dogs [27, 28]. In doing so, every dog was 
surveyed by a gamma camera/8-slice CT to derive eight complete scanned images 
within 72 hours. The raw outputs were processed with a self-developed program 
run in MATLAB to compose a thorough scenario of time-dependent Ga-67 nuclides’ 
intensity changes among multiple compartments (organs or tissues) for dogs that 
underwent a nuclear examination after being injected the Ga-67-citrate. Each 
canine patient was administered 22.2 MBq (0.6 mCi) Ga-67 citrate solution via the 
intravenous injection. The Ga-67 citrate solution was carrier-free with radionuclide 
and radiochemical purity values exceeding 99.9 and 95.0%, respectively. All radio-
pharmaceutical capsules were fabricated by the Syncor International Corporation 
(USA). The position-sensitive gamma ray emitted from the Ga-67 dose admin-
istration for each study object could be robustly assessed and plotted for further 
analysis. Figure 5 depicts the eight-compartmental biokinetic model of Ga-67 in 
liver figuring in the ICRP-30 report, which contains: (1) body fluid, (2) liver, (3) 
gastrointestinal (GI) tract, (4) kidney, (5) heart, (6) remainder, (7) bladder, and 
(8) excretion.
Figure 6 illustrates the fragments of scans obtained for a canine patient with 
liver carcinoma via a gamma camera: (A) The gamma camera/8 slice CT (GE 
Discovery NM/CT 670) facility indicates that the anesthetized dog was placed 
between two NM plates for scanning; (B) Close-up view of the anesthetized dog; 
(C) Particular scans were quoted directly from the E-CAM and implied the raw data 
Figure 5. 
A simplified biokinetic model of Ga-67 in the liver can be defined by eight major compartments: (1) body 
fluid, (2) liver, (3) gastrointestinal tract (GI tract), (4) kidney, (5) heart, (6) remainder, (7) bladder and  
(8) excretion according to ICRP-30 report.
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of 15 min counting after 72 elapsed hours. Here, the full-size scanning of the dog 
contained regions of interest (ROI), indicated as follows: ROI0 (whole-body), ROI1 
(heart), ROI2 (liver), and ROI3 (GI tract), ROI4 (kidney), and ROI5 (bladder); 
(D) The fusion plot from gamma camera and CT scanning. The CT was preset at 
130 kV, 150 mA, 0.8 sec., spin width 0.625 mm, spiral speed 3.75 mm/s, and matrix 
size 512 × 512. The remainder was defined by subtracting all defined compartments 
(ROI1–5) from the whole body (ROI0).
Figure 6. 
(A) The gamma camera/8 slice CT (GE discovery NM/CT 670) facility indicates that the anesthetized dog was 
placed between two NM plates for scanning; (B) close up view of the anesthetized dog; (C) particular scans 
were quoted directly from the E-CAM and implied the raw data of fifteen-minutes’ counting after 72 elapsed 
hours. Here, the full-size scanning of the dog contained regions of interest (ROI), indicated as follows: ROI0 
(whole-body), ROI1 (heart), ROI2 (liver), and ROI3 (GI tract), ROI4 (kidney), and ROI5 (bladder); (D) the 
fusion plot from gamma camera and CT scanning.
Canine Genetics, Health and Medicine
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Figure 7 shows the time-dependent curves of the Ga-67 concentration among 
various compartments for the dog with liver carcinoma.
Liver and GI Tract: In contrast to the I-131 thyroid model or GI Tract model for 
human patients, the model of Ga-67 for liver carcinoma dog was elaborated by the 
simplification of the general-purpose biokinetic model, according to the ICRP-30 
report. As seen in Figure 5, a complicated correlation among compartments allows 
one to use a MATLAB program to optimize the estimation via the empirical data 
[27]. The feedback path exists between compartments 2–6 and compartment 1. Each 
compartment has its biological half-life to transfer the Ga-67 radionuclides among 
compartments, which also confounds the theoretical estimation. Specifically, the 
liver provides a 22%-contribution of the body fluid (I12, 0.22), which is the second-
largest share, whereas the GI Tract has the largest share (I13, 0.33 ~ 0.43) after the 
Ga-67 administration. However, 60% (I21, 0.60) of the Ga-67 radionuclides returns 
as feedback to the body fluid with a biological half-life of 15 ~ 40 h. Meanwhile, 
the remaining nuclides of Ga-67 in GI Tract are transferred to the body fluid (I31), 
liver (I32), or directly to excretion (I38) with a biological half-life of 20 ~ 600 h. 
Noteworthy is that the effective half-life is defined as the reciprocal of the sum of 
reciprocal radiological and biological half-lives (1/T1/2(eff) = 1/T1/2(R) + 1/T1/2(bio)). 
Thus, in practice, either 600 or 20 h of biological half-life still perform as 69 or 
16 h of the effective half-life from the continuous gamma camera scanning. Some 
of Ga-67 radionuclides were found to migrate from the GI Tract to the liver (I32, 
0.2 ~ 0.7). Since portal vein circulation provides the blood flow from gastrointestinal 
section to the liver, the excessive blood pressure will slow the liver’s feedback path.
Kidney and bladder. Nearly 20% of Ga-67 nuclides were transferred to the 
kidney (I14, 0.2), exhibiting nearly no feedback to body fluid (I41, 0.07), in contrast 
to the bladder (I47, 0.93), and then were fully transferred to excretion (I78, 1.0).
Heart. Only 5–15% of Ga-67 nuclides were transferred to the heart (I15, 0.05–0.15), 
whereas most of them exhibited an instant feedback to body fluid (I51, 0.99) with a 
short biological half-time T1/2 of 18–20 h. The derived biological half-life of the heart 
can be treated as a group of cardiac muscles, which provide the blood circulation loop 
in the whole body, with no apparent Ga-67 nuclides’ repository effect.
A long biological half-life of liver for the liver carcinoma dog (40 h vs. 35 h or 
15 h) reveals a potential risk of hepatic disorder, whereas the remaining data are 
Figure 7. 
The time-dependent curves of the Ga-67 concentration among various compartments for a liver carcinoma dog.
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barely available to solidify the syndrome of liver carcinoma. The evolution of Ga-67 
in the liver carcinoma survey model still plays an essential role in veterinary and 
human medical domains, since it quantifies the time-dependent concentration of 
Ga-67 nuclides among compartments of the case–control group and allows one to 
acquire robust raw data via in-vivo scanning.
3. Global state-of-the-art treatment
3.1 Hepatectomy
The liver surface is convex and it slightly touches the diaphragm. The liver is 
located on the left side of the caudoventral tract, contacting the stomach, duo-
denum, pancreas, and right kidney. There are six hepatic lobes: right medial and 
lateral, left medial and lateral, and quadrate and caudate lobes. The gallbladder is 
located between the right medial and quadrate lobes. The liver has two so-called 
afferent (ingoing) blood supplies: the portal system and the arterial system, while 
the efferent (outgoing) blood flow of the liver circulation is through the hepatic 
veins. The hepatic lobules, which are the basic functional units of the liver, are 
cross-sectioned in a hexagonal shape and the portal triads in the periphery. Portal 
triads consist of the hepatic artery, portal vein, and bile duct. From the anatomic 
and histologic views, the liver is complicated, and hepatic tissue is friable. Partial 
lobectomy is difficult and may injure blood vessels and bile ducts in canine patients 
with bleeding disorders. Many techniques for partial and complete liver lobe resec-
tion have been introduced, and numerous stapling instruments have been adopted 
for both lobectomies. The survey of Liptak et al. [1], which covered 48 dogs with 
large massive hepatocellular carcinomas during a decade, revealed that their median 
survival time exceeded 1,460 days after the hepatectomy procedure. However, 
numerous complications, including ongoing anemia, hepatopathy, ileus, and lack 
of appetite, are frequently after liver surgery. Therefore, a proper intensive care is 
recommended to mitigate these complications and minimize the related risks.
3.2 Chemotherapy
The most commonly chemotherapy is administered intravenously. According to 
clinical chemotherapeutic management of neoplastic cases, a significant advance 
in veterinary practice is observed. However, a large share of HCC canine patients 
cannot be cured by chemotherapy and require a further integration of conven-
tional treatment modalities, such as surgery, radiation therapy, and innovative 
chemotherapy methods. Chemotherapeutic agents are generally administered at 
the maximum tolerated dose and at the highest dose intensity that is usually used in 
combination. Four advantages of combination chemotherapy include an increased 
log-kill, prevention of cancer drug resistance, targeting both dividing and resting 
cells, and allowing for lower doses with less toxicity [6]. Chemotherapeutic agents 
damage activated pathogenic cells but also affect normal tissues that divide rapidly 
and are sensitive to anti-mitotic drugs, such as cells in the bone marrow, diges-
tive tract, and hair follicles. The most common side-effects of chemotherapy are 
myelosuppression, mucositis, and alopecia. In general, malignant tumors cannot be 
wholly removed surgically and imply a poor prognosis for canine patients. Palliative 
chemotherapy and other treatments may be gradually applied to delay the tumor 
progression. Any further health care should involve close monitoring and minimi-
zation of side effects.
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3.3 Radiotherapy
As a general rule, surgical resection is considered the best treatment option if a 
primary tumor can be completely excised. If the region of extensive involvement, 
normal tissue, or volume of liver tumor make its complete removal problematic, 
then radiotherapy may be recommended by veterinarians as a palliative treatment 
of liver tumors. Its effectiveness against the canine liver tumor is limited by the fact 
that canine patients cannot tolerate cumulative doses exceeding 30 Gy [29]. A share 
of radiotherapy treatment in US veterinary facilities in 2001 study did not exceed 
20% [30], while 92% of facilities in 2010 used the 3D computerized radiotherapy, 
and 20–100% (with median of 50%) of facilities implemented computer simula-
tion treatment plans [31]. It should be noted the abdominal movement caused by 
breathing during radiotherapy of liver tumors strongly deteriorates the therapeutic 
effect, which issue can be resolved for human patients but is hard to control with 
canine ones.
4. TCVM treatment
4.1 Etiology and pathology
The available methods of animal cancer treatment imply separate or com-
bined application of surgery, radiation therapy, and chemotherapy targeted at the 
particular cancer cells. However, there is also a general concern about the quality 
of life of pets/canine patients. This gives much space to the alternative medicine, 
in particular, the traditional Chinese veterinary medicine (TCVM), which not 
only focuses on the tumor but also accounts for the overall health condition by 
regulating the so-called Yin and Yang constituents. Through the balance of Yin 
and Yang, the patients suffering from the disease could also improve their physi-
cal health. Tumor, in the TCVM perspective, is the morphological tissue struc-
ture change, which imply functional changes of the specific organs or tissues. 
Those pathological changes of tissues are defined by TCVM as phlegm, toxin, 
dampness, blood, and stasis. Therefore, the tumor’s mechanism can be briefly 
summarized from the TCVM standpoint as stagnation of blood or (heat-) toxin, 
accumulative dampness or phlegm, and Qi (energy) stagnation. The stagnation 
or lack of a free Qi/Blood movement results in the formation of pathological 
tumors in human and animal patients. Those with hepatic carcinomas often have 
the hormone/gastrointestinal symptoms [Liver (wood) Ke Spleen (Earth)] caus-
ing the Spleen Qi deficiency.
Spleen Qi is responsible for food intake and digestion; this process is called 
transformation and transportation. Both two functions of the spleen are critical 
for the production of Zheng Qi. Zheng Qi deficiency mainly focuses on the root of 
neoplastic formation. Zheng Qi is composed of Nutritive Qi and Defensive Qi (Wei 
Qi). As Wei Qi is a defensive deficiency, several external pathogenic factors (cold, 
wind, heat, summer heat, dryness, and dampness) cannot be easily detected and 
expelled from the body. These pathogenic factors will cause the blocking of Qi and 
impede the blood circulation. However, some other factors should be considered: 
emotional stress, unhealthy diet/lifestyle, and the environment. For example, 
negative emotional stress, inappropriate diet, and too humid environment are 
considered by TCVM as induction factors that trigger a liver tumor. Both internal 
and external factors may contribute to phlegm, Qi, and Blood stagnation, blood 
stasis, and ultimately lead to neoplasia [12, 19, 21, 22].
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4.2 Pattern differentiation and treatment
The TCVM has been used as an alternative treatment for years in Asia. However, 
its current applications to domestic animals/pets suffering from carcinomas are 
based on individual expert opinions, while there are no outlined veterinary treat-
ment strategies and guidelines for clinical practice in this field. The most lucrative 
concept accepted nowadays is a comprehensive combination of global/Western 
and TCVM components, the latter being aimed at adjunct therapy and recurrence 
prevention. Adjunct therapy should reduce the side-effects of chemotherapy, radia-
tion therapy, and surgery. Based on the pattern differentiation, it is essential to treat 
the liver tumor using TCVM drugs and acupuncture techniques capable of regulat-
ing Qi, nourishing blood, strengthening the body and organs, and improving the 
resistance to pathogenic factors. The TCVM is likely to improve the canine patient’s 
general conditions, remove the disease/pathogen, inhibit oncogenesis, alleviate 
side-effects, and improve the survival rate as shown in Figure 8.
The TCVM treatment is usually provided to canine patients undergoing a surgi-
cal treatment or after radiotherapy/chemotherapy. In most of these patients, tumors 
could not be eliminated entirely, and the adjunct treatment should improve their 
Figure 8. 
Acupuncture points. (A) LU 9: In the depression distal palmar to the most medial prominence of the radial 
styloid process, overlying the radiocarpal joint, medial to the radial artery, and the tendon of the flexor carpi 
radialis muscle. LI 10: In the depression in the muscular groove between the extensor carpi radialis and the 
common digital extensor mm. Of the forelimb, two cun distal to the transverse cubital crease. This is most 
evident when the elbow is flexed.LI 11: In the depression in the transverse cubital crease, just cranial to the 
lateral epicondyle of the humerus, between the extensor carpi radialis and common digital extensor mm. 
This point is easily palpated when the elbow is flexed. (B) LI 4: In the depression between the 2nd and 3rd 
metacarpal bones, approximately in the middle of the 2nd metacarpal bone. GV 14: In the depression on 
the midline between the dorsal spinous processes of the 7th cervical and 1st thoracic vertebrae. BL 20: In the 
depression, 1.5 cun lateral to the caudal border of the spinous process of the 12th thoracic vertebra. BL21: In the 
depression, 1.5 cun lateral to the caudal border of the spinous process of the 13th thoracic vertebra. BL 20: In 
the depression, 1.5 cun lateral to the caudal border of the spinous process of the 12th thoracic vertebra. BL22: In 
the depression, 1.5 cun lateral to the caudal border of the spinous process of the 1st lumbar vertebra. (C) LIV 
3: In the depression on the dorsum of the rear foot, between the 2nd and 3rd metatarsal bones, at the level of 
the junction of their heads and shaft, just proximal to their associated metatarsophalangeal joints. SP 6: In the 
depression 3 cun proximal to the tip of the tibia’s medial malleolus, on the caudal border of the tibia. GB34: 
In the depression cranial and distal to the head of the fibula. ST36: In the depression, just lateral to the distal 
aspect of the cranial border of the tibial tuberosity (tibial crest), approximately in the middle of the cranial 
tibialis muscle.
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quality of life, maintain their physical condition, and prolong survival time. TCVM 
has shown significant efficacy in the symptomatic treatment of canine patients 
suffering from the deficiency of vital Qi, leading to physical pain, fever, anorexia, 
nausea, gastrointestinal problems, fatigue, and constipation. Although liver heat 
and dampness are considered as the most probable causes for the formation of 
liver carcinoma and viral hepatitis in human patients, the animal/canine ones are 
less prone to viral pathogens. From the TCVM perspective, there are two patterns 
controlling liver carcinomas in small animals/dogs.
4.2.1 The first pattern: “blood stasis with Qi deficiency”
The Qi deficiency is more specifically related to “Spleen Qi deficiency”, leading 
to “Blood Stasis”. The main TCVM principles are to improve blood circulation, 
nourish the blood, resolve the stagnation or accumulation, tonify the spleen, and 
relieve pain. Refer to Table 4; acupuncture on specific points can improve and 
enhance the symptoms described earlier. Xiao Yao San, which is compounded by 
various herbs, is a transitional Chinese medicine described in the “Formulary of 
the Tai Ping Welfare Dispensary Bureau’ Collections of Medicinal Formulations” 
compiled by Chen Shi-wen et al. in 1151. A modified herb formula of Nei Xiao 
Wan, called “Stasis Breaker”, has been introduced by Xie et al. specifically for 
animals [19, 32] to reduce phlegms and stasis, clear toxin substances, and promote 
Qi and Blood circulation. The significant effect of “Stasis Breaker” breaks the 
blood stasis, softening the hard nodes and tumors. Furthermore, some studies 
prove that Bai Hua She She Cao and Ban Zhi Lian can inhibit cell mutation, tumor 
growth and clear the “heat-toxin” [19, 33, 34].
4.2.2 The second pattern of liver carcinoma: “blood stasis with Yin deficiency”
Heat and liver stagnation are supposed by TCVM to result in Qi and Blood stag-
nation. The consumption of fluid will injure the Yin in the Middle Burn. Once Liver 
Yin and Kidney Yin are injured, the tumor will be gradually formed. This treatment 
pattern focuses on nourishing Yin and Blood, resolving pain and stagnation, tonify-
ing Qi, and resolving tumor. The recommended acupuncture points are shown 
in Table 4. [35]. Yi Guan Jain, a herbal medicine, described in the “Supplement 
to the Classified Case Records of Famous Physicians” by Wei Zhi-Xiu in 1770. It is 
intended to tonify the Liver’s and Kidney’s Yin and clear the “false heat”. The combi-
nation of Yi Guan Jain and “Stasis breaker” effectively improves the immune system 
Symptom Acupuncture points
General Qi deficiency LI -10, ST-36, CV-17, LU-9
Spleen deficiency/eliminate phlegm BL-20, BL-21, ST-36, ST-40
Immunization GV-14, LI-4, LI-10, LI-11
Smooth Qi and relieve pain LIV-3, LIV-4, GB-34, GB-41
Anorexia CV-12, Shan-gen
Vomiting PC-6, GB-34, CV-12
Diarrhea GV-1, SP-6
Ascites SP-6, SP-9, BL-22,
Table 4. 
TCVM acupuncture points for tumor.
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performance, inhibiting tumor growth, mutation, and metastasis. This combina-
tion can also mitigate chemotherapy/radiotherapy side-effects and improve life 
quality [12, 19, 21, 22].
5. Conclusions
The global veterinary medicine is widely used to eliminate canine carcinogens 
by substantiated combinations of drug administration, surgery, chemotherapy, and 
radiotherapy treatments. However, their side-effects remain a challenging issue 
faced by clinical veterinarians and dog owners. In this respect, traditional Chinese 
veterinary medicine (TCVM), including acupuncture, herbs, food therapy, and 
massage, is considered a lucrative integrated treatment system. Using the pattern 
differentiation, as well as the proposed biokinetic Ga-67 model of canine liver 
carcinoma, the robust HCC diagnosis of canine patents can be obtained. A further 
application of global state-of-the-art and/or TCVM-based therapies can enhance 
the immune system, speed up the recovery, relieve pain syndrome, reduce chemo-
therapy toxicities, and improve quality of life of canine patients. Thus, the global 
integrative oncology comprehensively combines regulated clinical treatments 
with complementary and alternative medicine (TCVM in particular), yielding the 
synergistic curing effect.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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